Wobenzym (Wobenzym)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbspenteric coated tablets
Composition:Active substances:

Pancreatin 345 prot.Evr.Pharm.-Ed., Papain 90 F.I.P-Ed., Rutoside 3 H2O 50.00 mg, bromelain 225 F.I.P.-Ed., Trypsin 360 F.I.P.-Ed .. lipase 34 F.I.P.-Ed., Amylase 50 F.I.P.-Ed., Chymotrypsin 300 F.I.P.-Ed.

Excipients:

Lactose, corn starch, magnesium stearate, stearic acid, purified water, silicon dioxide colloid, talc.

Sucrose, talc, methacrylic acid-methyl methacrylate copolymer, shellac, titanium dioxide, white clay, yellow-orange colorant S (E110), crimson 4R (E124), povidone, macrogol 6000, triethyl citrate, vanillin, bleached wax, carnauba wax.

Description:Round biconvex tablets with a smooth surface, with a characteristic odor, painted in a red-orange color. Variations in the color intensity of the outer shell from red-orange to red are allowed.
Pharmacotherapeutic group:Anti-inflammatory, immunomodulating agent
ATX: & nbsp
  • Other immunostimulants
    • Pharmacodynamics:VOBENZIM is a combination of natural enzymes of plant and animal origin. Entering the body, the enzymes are absorbed in the small intestine by resorption of intact molecules and, when bound to the transport proteins of the blood, enter the bloodstream.Subsequently, enzymes migrating along the vascular bed and accumulating in the zone of the pathological process have immunomodulatory, anti-inflammatory, fibrinolytic, anti-edema, antiplatelet and secondary analgesic effects.

    VOBENZIM has a positive effect on the course of the inflammatory process, it limits the pathological manifestations of autoimmune and immunocomplex processes, positively influences the immunological reactivity of the organism. It stimulates and regulates the level of functional activity of monocyte-macrophages, natural killer cells, stimulates antitumor immunity, cytotoxic T-lymphocytes, and phagocytic activity of cells.

    Under the influence of VOBENZIMA, the number of circulating immune complexes decreases and the membrane deposits of immune complexes from tissues are removed.

    VABENZIM reduces infiltration of interstitium by plasma cells. Increases the elimination of protein detritus and fibrin deposits in the inflammation zone, accelerates the lysis of toxic metabolic products and necrotic tissues.It improves resorption of hematomas and edema, normalizes the permeability of the walls of blood vessels.

    VABENZIM reduces the concentration of thromboxane and the aggregation of platelets. Regulates the adhesion of blood cells, increases the ability of red blood cells to change their shape, regulating their plasticity, normalizes the number of normal discocytes and reduces the total number of activated platelets, normalizes blood viscosity, reduces the total number of microaggregates, thereby improving microcirculation and rheological properties of blood, as well as supplying tissues oxygen and nutrients.

    VOBENZIM reduces the severity of side effects associated with taking hormonal drugs (hypercoagulation, etc.).

    VABENZIM normalizes lipid metabolism, reduces the synthesis of endogenous cholesterol, increases the content of high-density lipoproteins, reduces the level of atherogenic lipids, improves the absorption of polyunsaturated fatty acids.

    VOBENZIM increases the concentration of antibiotics in the blood plasma and inflammation focus, thus increasing the effectiveness of their use. At the same time, enzymes reduce the undesirable side effects of antibioticoterapia (dysbacteriosis), by improving the environment.

    VOBENZIM regulates the mechanisms of nonspecific protection (the production of interferons), thereby demonstrating antiviral and antimicrobial effects.

    Indications:Applicable in complex therapy the following diseases:

    Angiology: thrombophlebitis, treatment of post-thrombophlebitis and acute thrombophlebitis of superficial veins, endarteritis and obliterating atherosclerosis of lower extremity arteries, prevention of recurrent phlebitis, lymphatic edema.

    Urology: cystitis, cystopyelitis, prostatitis, sexually transmitted infections.

    Gynecology: chronic infections of the genitals, adnexitis, gestosis, mastopathy, to reduce the frequency and severity of side effects of hormone replacement therapy.

    Cardiology: angina pectoris, subacute stage of myocardial infarction (to improve the rheological properties of the blood).

    Pulmonology: sinusitis, bronchitis, pneumonia.

    Gastroenterology: pancreatitis, hepatitis.

    Nephrology: pyelonephritis, glomerulonephritis.

    Endocrinology: Diabetic angiopathy, diabetic retinopathy, autoimmune thyroiditis.

    Rheumatology: Rheumatoid arthritis, reactive arthritis, Bechterew's disease.

    Dermatology: atopic dermatitis, acne.

    Surgery: prevention and treatment of postoperative complications (inflammation, thrombosis, edema), adhesions, posttraumatic and lymphatic edema, plastic and reconstructive surgeries.

    Traumatology: traumas, fractures, distortions, ligamentous apparatus injuries, bruises, chronic posttraumatic processes, inflammations of soft tissues, burns, injuries in sports medicine.

    Neurology: multiple sclerosis.

    Pediatrics: atopic dermatitis, infectious and inflammatory airway diseases (inflammation of the upper and lower respiratory tract infections, pneumonia), juvenile rheumatoid arthritis, prevention and treatment of postoperative complications (suppuration and poor wound healing, the formation of adhesions, local edema).

    Ophthalmology: uveitis, iridocyclitis, hemophthalmus, diabetic retinopathy, ophthalmosurgery.

    Prevention: disorders of microcirculation, post-stress disorders, as well as disruption of adaptation mechanisms. Prevention of side effects of hormone replacement therapy, hormonal contraception. When surgical interventions to prevent infections and adhesions.

    VABENZIM It is recommended to prevent infectious complications and improve the quality of life during chemotherapy or radiotherapy. Prevention of the development of viral infections and their complications.

    Contraindications:Individual intolerance to the drug. Diseases associated with an increased likelihood of bleeding (hemophilia, thrombocytopenia, etc.). Conduction of hemodialysis. Children under 5 years.
    Pregnancy and lactation:Pregnancy and lactation are not a contraindication for the use of the drug, however, pregnant women should take VOBENZIM under the supervision of a doctor.
    Dosing and Administration:Tablets should be taken orally, at least 30 minutes before meals, without chewing, washing with water (200 ml.).

    Adults

    Depending on the activity and severity of the disease, VOBENZIM is taken at a dose of 3 to 10 tablets 3 times a day. In the first three days of taking the drug, the recommended dose is 3 tablets 3 times a day.

    With an average activity of the disease, VABENZIM is prescribed in a dose of 5-7 tablets 3 times a day for 2 weeks. In the future, the dose of VOBENZIMA should be reduced to 3-5 tablets 3 times a day, the course is 2 weeks.

    With high activity of the disease, VOBENZIM is prescribed in a dose of 7-10 tablets 3 times a day for 2-3 weeks. In the future, the dose of VOBENZIMA is reduced to 5 tablets 3 times a day, the course is 2-3 months.

    In chronic long-term diseases, VOBENZIM can be used according to indications by courses from 3 to 6 months or more.

    To increase the effectiveness of antibiotics and prevent dysbacteriosis, VOBENZIM should be used throughout the course of antibiotic therapy in a dose of 5 tablets 3 times a day. After stopping the course of antibiotics to restore the microflora (biocenosis) of the intestine VOBENZIM should be given 3 tablets 3 times a day for 2 weeks.

    As a therapy for "cover" during chemotherapy and radiotherapy, VOBENZIM should be used at a dose of 5 tablets 3 times a day before the completion of chemotherapy and radiation therapy; to prevent infectious complications, to improve the tolerability of basic therapy and to improve the quality of life.

    When using VOBENZIMA for preventive purposes, the dose of the drug is 3 tablets 3 times a day, the course is 1.5 months with a repetition of 2-3 times a year.

    Children

    Children from 5 to 12 years - 6 kg of the weight of the child 1 tablet per day.From 12 years old according to the scheme for adults. Dosage and duration of treatment depend on the severity of the disease and are determined by the doctor.

    Side effects:VOBENZIM is well tolerated by patients. In most cases of side effects, withdrawal syndrome, addiction was not observed even with long-term treatment with high doses. In some cases, minor changes in the consistency and odor of the stool, skin rashes in the form of urticaria, which occur with a decrease in the dose of the drug or withdrawal.

    If other adverse reactions not noted in the instructions appear, it is recommended that you stop taking the drug and consult a doctor.

    Overdose:Cases of drug overdose are unknown.
    Interaction:With the simultaneous administration of VOBENZIMA with other medications, incompatibilities are not described.
    Special instructions:In the case of infectious processes, VOBENZIM does not replace antibiotics, but increases their effectiveness, increasing the concentration in the blood plasma and inflammation focus.

    It should be borne in mind that at the very beginning of taking the drug the symptoms of the disease can worsen, in such cases, treatment should not be interrupted, but a temporary reduction in the dose of the drug is recommended.

    The drug is not doping and does not have a negative impact on driving and performance of work requiring high speed of mental and physical reactions.

    Form release / dosage:Tablets, covered with enteric coating.
    Packaging:Tablets are packed in blisters of 20 pcs. and placed in cardboard boxes of 2, 5 and 10 blisters with a nested instruction for medical use.

    Packaging - 800 tablets contains tablets in high density polyethylene bottles with enclosed instructions for medical use.

    Storage conditions:List B.

    In a dry dark place at a temperature of 15 to 25 ° C, out of reach of children.

    Shelf life:2.5 years. Do not use after the expiration date indicated.
    Terms of leave from pharmacies:Without recipe
    Registration number:П N011530 / 01
    Date of registration:19.02.2010 / 20.07.2015
    Expiration Date:Unlimited
    The owner of the registration certificate:MUKOS PHARMA GmbH & Co. MUKOS PHARMA GmbH & Co. Germany
    Manufacturer: & nbsp
    Representation: & nbspMUKOS PHARMA GmbH & Co. MUKOS PHARMA GmbH & Co. Germany
    Information update date: & nbsp01.03.2017
    Illustrated instructions
      Instructions
      Up